利用囊性纤维化生物标志物绘制可靶向的炎症图谱及研究结果
Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.
作者信息
Giddings Olivia, Esther Charles R
机构信息
Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
出版信息
Pediatr Pulmonol. 2017 Nov;52(S48):S21-S28. doi: 10.1002/ppul.23768. Epub 2017 Jul 17.
Abstract
Cystic fibrosis is characterized by an overly exuberant neutrophilic inflammatory response to pathogens and other stimuli that starts very early in disease. The overwhelming nature of this response is a primary cause of remodeling and destruction of the airways, suggesting that anti-inflammatory therapies could be beneficial in CF. However, finding therapies that can effectively reduce the inflammatory response without compromising host defenses remains elusive. New approaches towards mapping inflammatory targets promise to aid in developing novel therapeutic strategies and improve outcomes in individuals with CF.
摘要
囊性纤维化的特征是对病原体和其他刺激产生过度旺盛的嗜中性粒细胞炎症反应，这种反应在疾病早期就开始了。这种反应的压倒性本质是气道重塑和破坏的主要原因，这表明抗炎疗法可能对囊性纤维化有益。然而，找到能够有效减轻炎症反应而又不损害宿主防御能力的疗法仍然难以实现。绘制炎症靶点的新方法有望有助于开发新的治疗策略并改善囊性纤维化患者的治疗效果。
相似文献
1
Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.
Pediatr Pulmonol. 2017 Nov;52(S48):S21-S28. doi: 10.1002/ppul.23768. Epub 2017 Jul 17.
2
Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis.
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):423-32. doi: 10.1177/039463201102400215.
3
[Examination of exhaled breath condensate in cystic fibrosis].
Cas Lek Cesk. 2010;149(4):173-7.
4
New and emerging therapies for pulmonary complications of cystic fibrosis.
Drugs. 2001;61(10):1379-85. doi: 10.2165/00003495-200161100-00001.
5
Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
Pediatr Pulmonol. 2010 Feb;45(2):107-17. doi: 10.1002/ppul.21154.
6
Identifying novel endpoints for cystic fibrosis clinical trials.
Adv Pediatr. 2005;52:115-27. doi: 10.1016/j.yapd.2005.03.007.
7
Biomarkers in Paediatric Cystic Fibrosis Lung Disease.
Paediatr Respir Rev. 2015 Sep;16(4):213-8. doi: 10.1016/j.prrv.2015.05.004. Epub 2015 May 12.
8
Steady-State Therapy with Azithromycin or Low-Dose Prednisolone in Paediatric Cystic Fibrosis Patients: Inflammatory Markers and Disease Progression.
Int Arch Allergy Immunol. 2017;172(1):45-54. doi: 10.1159/000453451. Epub 2017 Feb 21.
9
Noninvasive biomarkers of airway inflammation in cystic fibrosis.
Curr Opin Pulm Med. 2003 Nov;9(6):516-21. doi: 10.1097/00063198-200311000-00012.
10
Use of modulators of airways inflammation in patients with CF.
Clin Rev Allergy Immunol. 2002 Aug;23(1):29-39. doi: 10.1385/CRIAI:23:1:029.
引用本文的文献
1
Evolution and Prognostic Variables of Cystic Fibrosis in Children and Young Adults: A Narrative Review.
Diagnostics (Basel). 2025 Aug 2;15(15):1940. doi: 10.3390/diagnostics15151940.
2
Cellular imbalance in proximal and distal lung of CFTR sheep in utero and at birth.
Mol Med. 2025 Jun 11;31(1):231. doi: 10.1186/s10020-025-01266-7.
3
Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases.
Int J Mol Sci. 2024 Feb 5;25(3):1933. doi: 10.3390/ijms25031933.
4
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
Clin Chest Med. 2022 Dec;43(4):647-665. doi: 10.1016/j.ccm.2022.06.007.
5
Metabolomics of airways disease in cystic fibrosis.
Curr Opin Pharmacol. 2022 Aug;65:102238. doi: 10.1016/j.coph.2022.102238. Epub 2022 May 29.
6
Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis.
PLoS One. 2022 May 6;17(5):e0267986. doi: 10.1371/journal.pone.0267986. eCollection 2022.
7
Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients.
Respir Res. 2019 Dec 21;20(1):290. doi: 10.1186/s12931-019-1214-8.
本文引用的文献
1
The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis.
Thorax. 2017 Dec;72(12):1104-1112. doi: 10.1136/thoraxjnl-2016-209279. Epub 2017 Mar 9.
2
Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies.
Eur Respir J. 2017 Jan 4;49(1). doi: 10.1183/13993003.00903-2016. Print 2017 Jan.
3
Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease.
J Cyst Fibros. 2017 Mar;16(2):214-221. doi: 10.1016/j.jcf.2016.10.012. Epub 2016 Nov 24.
4
Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.
Eur Respir J. 2016 Dec;48(6):1612-1621. doi: 10.1183/13993003.00524-2016. Epub 2016 Nov 11.
5
Cystic Fibrosis Lung Immunity: The Role of the Macrophage.
J Innate Immun. 2016;8(6):550-563. doi: 10.1159/000446825. Epub 2016 Jun 24.
6
Biomarkers in Exhaled Breath Condensate Are Not Predictive for Pulmonary Exacerbations in Children with Cystic Fibrosis: Results of a One-Year Observational Study.
PLoS One. 2016 Apr 6;11(4):e0152156. doi: 10.1371/journal.pone.0152156. eCollection 2016.
7
Airway acidification initiates host defense abnormalities in cystic fibrosis mice.
Science. 2016 Jan 29;351(6272):503-7. doi: 10.1126/science.aad5589.
8
On the Pathogenesis of Acute Exacerbations of Mucoobstructive Lung Diseases.
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S160-3. doi: 10.1513/AnnalsATS.201507-460AW.
9
Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis.
Nat Commun. 2015 Sep 29;6:8382. doi: 10.1038/ncomms9382.
10
Inflammation and its genesis in cystic fibrosis.
Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S39-56. doi: 10.1002/ppul.23242.
Zotero 插件